MeDiGes Study: Metformine Use in Gestational Diabetes

Launched by FUNDACIÓN PÚBLICA ANDALUZA PARA LA INVESTIGACIÓN DE MÁLAGA EN BIOMEDICINA Y SALUD · Jan 7, 2020

Keywords

ClinConnect Summary

Women with gestational diabete (GD) who do not meet glycemic control objectives with diet will be assigned to two treatment groups randomly. One: metformin at a dose of 850-2550mg every 24h; two: insulin detemir associated or not with rapid insulin analogue (aspart) according to your glycemic controls. The Metformin group may additionally receive insulin in a second time in case the glycemic control is not appropriate with monotherapy.

The objectives are: Demonstrate that treatment with metformin in women with GD (not controlled with diet) can get no lower obstetric and perinatal outcomes ...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. 18-45 years old.
• • 2. Diagnosis of GD, with fasting glucose \<120 mg / dL.
• • 3. not controlled by diet: fasting capillary blood glucose\> 95 mg / dl in at least 2-3 times or 1 hour postprandial \>140 mg / dl on, at least 2-3 times a week.
• • 4. 2nd or 3rd trimesters of pregnancy.
• • 5. Able to give informed consent.
• Exclusion Criteria:
• • 1. Psychopathological situations that do not guarantee proper adhesion to follow up
• • 2. 1st trimester of pregnancy
• • 3. gastrointestinal diseases that may cause poorer tolerance or increased symptoms with metformin.
• • 4. Patients who can not attend the scheduled consultation.
• • 5. Language barrier limiting for understanding treatment settings
• • 6. Twin pregnancy.